Tamarack Advisers’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-125,000
| Closed | -$1.61M | – | 26 |
|
|
2023
Q2 | $1.61M | Sell |
125,000
-75,000
| -38% | -$968K | 0.5% | 23 |
|
|
2023
Q1 | $2.64M | Sell |
200,000
-30,000
| -13% | -$396K | 0.96% | 16 |
|
|
2022
Q4 | $3.45M | Buy |
230,000
+30,000
| +15% | +$450K | 1.78% | 16 |
|
|
2022
Q3 | $2.36M | Hold |
200,000
| – | – | 1.39% | 23 |
|
|
2022
Q2 | $2.26M | Sell |
200,000
-125,000
| -38% | -$1.41M | 1.31% | 22 |
|
|
2022
Q1 | $9.72M | Sell |
325,000
-125,000
| -28% | -$3.74M | 4.6% | 7 |
|
|
2021
Q4 | $11.9M | Sell |
450,000
-250,000
| -36% | -$6.63M | 4.9% | 6 |
|
|
2021
Q3 | $25.4M | Buy |
700,000
+60,000
| +9% | +$2.18M | 8.02% | 2 |
|
|
2021
Q2 | $27.8M | Sell |
640,000
-195,000
| -23% | -$8.46M | 7.87% | 2 |
|
|
2021
Q1 | $28.6M | Buy |
835,000
+90,000
| +12% | +$3.08M | 5.86% | 3 |
|
|
2020
Q4 | $26M | Sell |
745,000
-5,000
| -0.7% | -$174K | 5.41% | 4 |
|
|
2020
Q3 | $18M | Buy |
750,000
+65,000
| +9% | +$1.56M | 5.55% | 5 |
|
|
2020
Q2 | $12.5M | Buy |
685,000
+130,000
| +23% | +$2.38M | 3.49% | 11 |
|
|
2020
Q1 | $8.66M | Sell |
555,000
-20,000
| -3% | -$312K | 3.28% | 12 |
|
|
2019
Q4 | $11.8M | Buy |
575,000
+27,500
| +5% | +$564K | 2.69% | 18 |
|
|
2019
Q3 | $10.2M | Hold |
547,500
| – | – | 2.67% | 12 |
|
|
2019
Q2 | $14M | Buy |
547,500
+17,500
| +3% | +$448K | 4.26% | 10 |
|
|
2019
Q1 | $13.6M | Sell |
530,000
-20,000
| -4% | -$514K | 5.41% | 7 |
|
|
2018
Q4 | $12.7M | Buy |
550,000
+95,000
| +21% | +$2.19M | 5.16% | 10 |
|
|
2018
Q3 | $14.6M | Buy |
455,000
+192,500
| +73% | +$6.18M | 4.17% | 9 |
|
|
2018
Q2 | $7.43M | Buy |
+262,500
| New | +$7.43M | 2.49% | 15 |
|